



Bachem and Jitsubo enter into exclusive Licensing Agreement

Bubendorf/Basel, Switzerland and Yokohama, Japan, May 8, 2020 – Bachem (SIX: BANB) and Jitsubo CO., LTD. announce today that they signed an exclusive Licensing Agreement for Jitsubo's Molecular Hiving™ technology. Under the License agreement, Jitsubo will develop selected manufacturing processes using their Molecular Hiving™ technology and transfer these processes to Bachem. Bachem will further optimize, scale up and produce for commercial applications. In return, Jitsubo will receive development fees and royalties.

Using this technology, Bachem expects reduced manufacturing costs, improved sustainability, greener chemistry, efficient scale up, and enhanced in-process controls. The two companies have been establishing a close collaboration and several projects for active pharmaceutical ingredients (APIs) as well as cosmetic peptides, have already been initiated and successfully realized using Jitsubo's technology at Bachem.

Dr. Günther Loidl, Chief Technology Officer of Bachem Holding AG, comments: "We are convinced that Jitsubo's Molecular Hiving™ technology offers substantial advantages regarding efficiency, and towards greener manufacturing. It complements Bachem's current extensive technology base and is a great fit for us because Bachem is already offering unique capabilities in the area of solid phase, hybrid, and solution phase peptide chemistry. We are excited to be the only contract manufacturing organization to offer this innovative technology to our customers."

Dr. Kazuaki Kanai, Chief Executive Officer of Jitsubo CO., LTD. continues: "It is a great pleasure for us having collaborated with the industry leader, Bachem, in exploring applications of our unique technology, Molecular Hiving™, and now having reached an exclusive License Agreement which will provide opportunities to deliver products to customers much faster and at greater scale. We will continue our development efforts broadening the technology base to meet various requirements from the society and hope to deliver meaningful products to customers through this collaboration and more importantly, to the patients in the world and realize our vision of "Enrich the world with smiles".

About Bachem

The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides. As a full service provider Bachem offers products for clinical development and commercial applications as well as a comprehensive catalog and exclusive custom synthesis. With 50 years of experience and

subsidiaries in Switzerland, the United States, the United Kingdom and Japan, Bachem is the partner of choice for the biotech and pharma industry worldwide.

Bachem. Leading Partner in Tides

About Jitsubo

Jitsubo is a pharmaceutical venture established in 2005 and has developed unique liquid phase peptide manufacturing technology, Molecular Hiving™, which provides low cost, high quality, environment friendly and ease of scale-up for the manufacturing of various peptides. Jitsubo as a research and manufacturing company, has been offering Molecular Hiving™ to global pharmaceutical companies as a contract manufacturer and/or working with CMO.

Enrich the world with smiles.

Contact:

For further questions, please visit our websites or contact the person below.

Bachem Holding AG

Stephan Schindler, CFO

Tel.: +41 58 595 2021

Fax: +41 58 595 2043

ir@bachem.com

<https://www.bachem.com/>

Jitsubo CO., LTD.

Marie Sato, Public Relations

Tel.: +81 45 633 4327

Fax: +81 45 633 4329

Sato@jitsubo.com

www.jitsubo.com/en